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Key Points 
Question: Can we identify DNA methylation signatures of depressive symptoms in middle-aged 
and elderly persons in the general populations in blood? 
Findings: In this large epigenome-wide association study of depressive symptoms, comprising of 
11,256 participants of European and African origin from 11 population-based cohorts, we 
identified three genomic sites significantly associated with depressive symptoms. All three sites 
are either in genes or have downstream effects on genes expressed in the brain, and converge 
to the axon guidance pathway. 
Meaning: Our study suggests that robust DNA methylation signatures of depression are 
identifiable in blood and these signatures may be similar across various ethnicities. 
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Abstract 
Importance: Depressive disorders arise from a combination of genetic and environmental risk 
factors, however, the pathophysiology and underlying molecular events leading to depression 
remain elusive. Epigenetic disruption provides a plausible mechanism through which gene-
environment interactions lead to depression. Large-scale epigenome-wide studies on 
depression are missing, hampering the identification of potentially modifiable biomarkers.   
Objective: To identify robust epigenetic mechanisms underlying depression in middle-aged and 
elderly persons using DNA methylation in blood. 
Design: We performed the first cross-ethnic meta-analysis of epigenome-wide association 
studies (EWAS) within the framework of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium.  
Setting: Discovery EWAS was performed in nine population-based cohorts. Results of the EWAS 
from all cohorts were pooled using sample-size weighted meta-analysis. Replication of the top 
epigenetic sites from the discovery stage was performed in two independent population-based 
cohorts.  
Participants: The discovery sample included 7,948 individuals of European origin and the 
replication sample included 3,308 individuals of African-American and European origin. Only 
participants that were assessed for both depressive symptoms and whole blood DNA 
methylation were included in the study. 
Outcome: Whole blood DNA methylation levels were assayed with Illumina-Infinium Human 
Methylation 450K BeadChip and depressive symptoms were assessed by questionnaire. 
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Results: The discovery cohorts consisted of 7,948 individuals (48% female) with a mean age of 
65.4 (SD=5.8) years. The replication cohort consisted of 3,308 individuals (74% female) with a 
mean age of 60.3 (SD=6.4) years. The EWAS identified methylation of three CpG sites including 
cg04987734 (p-value=1.57×10-8, n=11256, CDC42BPB gene), cg12325605 (p-value=5.24×10-9, 
n=11256, ARHGEF3 gene) and an intergenic CpG site cg14023999 (p-value=5.99×10-8, n=11256, 
chromosome=15q26.1) significantly associated with increased depressive symptoms. The 
predicted expression of CDC42BPB and ARHGEF3 was significantly associated with major 
depression in brain and fibroblasts, respectively.  
Conclusion: We report the first robustly associated methylated sites for depressive symptoms. 
All three findings point towards axon guidance as the common disrupted pathway in 
depression. Our findings provide new insights into the molecular mechanisms underlying the 
complex pathophysiology of depression. Further research is warranted to determine the utility 
of these findings as biomarkers of depression and evaluate any potential role in the 
pathophysiology of depression and their downstream clinical effects.  
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Introduction 
Depression is one of the most common mental health disorders that is projected to play a 
leading role in disease burden by the year 20301. In later life, depression is associated with 
disability, increased mortality, dementia and poor outcomes from physical illness2. Further, 
more people aged over 65 years commit suicide than in any other age group, and most have 
major depression3. Limited understanding of the molecular mechanisms underlying depression 
is a major bottleneck in the development of innovative treatment, prognostic markers, and 
prevention strategies. 
Studying depression is challenging, as it is a heterogeneous disorder with a multifactorial 
etiology4. This heterogeneity increases with age as the incidence of chronic diseases and 
disability rises. The contribution of genetics to the risk of depression is moderate with 
heritability estimates ranging from 40 to 50%5 and modest (18%) in the elderly6. Genome-wide 
association studies (GWAS) have recently identified numerous rare and common genetic 
variants associated with depression and related traits7-10. However, genetic variation alone does 
not completely explain an individual’s risk for developing depression. Among environmental 
factors, adverse life-events and stress are major risk factors for depression11. Converging 
evidence from animal and human studies suggest that psychosocial stressors trigger depression 
onset by inducing elevations in pro-inflammatory cytokines12. These psychosocial stressors are 
also known to influence epigenetic mechanisms, such as DNA methylation13 that can drive 
sustained changes in gene expression14. The high contribution of environmental factors to 
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depression in the elderly makes DNA methylation an interesting candidate mechanism for 
studies of the molecular basis of late-life depression.  
DNA methylation may be global or tissue-specific15. Tissues likely to be involved in complex 
psychiatric disorders, such as brain, are not directly accessible from living patients. The, use of 
post-mortem brain tissue to study DNA methylation is a possible solution, although obtaining a 
sufficient sample size is challenging16. To study differential DNA methylation associated with 
mental health symptoms on a large scale, peripheral tissues such as blood constitutes a useful 
proxy for detecting trans-tissue changes and the most appropriate tissue for biomarkers16,17. 
Moderate correlation has been demonstrated between blood and brain tissues at non-tissue 
specific regulatory regions across the methylome18. To date, several studies have assessed the 
correlation between depression and blood DNA methylation19,20. However, these studies have 
been limited to a small number of DNA methylation sites (CpGs) and/or small samples. For 
instance, the largest published epigenome-wide association study (EWAS) assessed brain DNA 
methylation in 76 cases persons who died during a depressive episode and 45 controls21. 
Moreover, these studies compared depressed cases with healthy controls. Depression 
represents an arbitrarily selected extreme of the continuum of varying severity and duration22, 
whereas a broad phenotype approach can be more representative for the general population. 
In a large study consisting of 252,503 individuals from 68 countries showed that sub-threshold 
depressive disorders produce significant decrements in health and do not qualitatively differ 
from full-blown episodes of depression23. A meta-analysis in individuals aged over 55 found two 
to three times higher prevalence of sub-threshold depressive symptomology than major 
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depression24. Use of rating scales have therefore been recommended for the assessment of 
depressive problems in the elderly2. 
In the current study, we performed EWAS of depressive symptoms using whole blood samples 
of 7,948 individuals of European ethnicity from the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium. We replicated our findings in 3,308 individuals of 
African-American and European ancestry. Finally, we used publicly available expression 
quantitative methylation (eQTM) loci and expression quantitative loci (eQTL) databases to 
identify the downstream effects of the associated methylation loci.  
Materials and Methods 
Study population 
The study sample for the discovery analysis included a total of 7,948 participants of European 
ancestry from nine population-based cohorts of the CHARGE consortium (Table 1): 
Cardiovascular Health Study (CHS)25, Framingham Heart Study (FHS)26, Helsinki Birth Cohort 
Study (HBCS)27, Cooperative Health Research in the Augsburg Region (KORA) study28, two sub-
cohorts from Lothian Birth-Cohort born in 1921 (LBC1921)29 and 1936 (LBC1936)30, two sub-
cohorts from Rotterdam Study (RS-III and RS-BIOS)31 and Generation Scotland: Scottish Family 
Health Study (GS) study32. These cohorts included community dwelling individuals, who were 
not selected based on disease status. Informed consent was obtained from all participants. The 
same cohorts have been successfully used to identify differentially methylated sites associated 
with cognitive traits33, inflammation34 and smoking35. The protocol for each study was approved 
by the institutional review board of each institution.  
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The replication sample included 3,308 participants, largely of African American origin from the 
Atherosclerosis Risk in Communities Study (ARIC)36 and European origin from the Women’s 
Health Initiative - Epigenetic Mechanisms of PM-Mediated Cardiovascular disease (WHI-EMPC) 
that joined the consortium later for the replication phase of the study37. Detailed information 
for each cohort is provided in the Supplementary Text. 
Depressive symptoms assessment 
Depressive symptoms were measured using self-reported questionnaires or structured 
interview performed by a trained researcher, psychologist, or psychiatrist at the same time 
point when blood samples were obtained for DNA methylation quantification (Table 1). Four 
cohorts (FHS, HBCS, RS-III, and RS-BIOS) assessed depressive symptoms using the 20-item 
Centre for Epidemiologic Studies Depression (CES-D) scale38, while CHS used the 10-item CES-D 
scale. Participants could score from zero to 60 (or 30 for CHS) points, where higher scores 
suggest more depressive symptoms. WHI-EMPC used a cohort specific CES-D/DIS screening 
instrument, which is described in detail in the Supplementary Text. The LBC1921 and LBC1936 
assessed self-reported depressive symptoms using the Hospital Anxiety and Depression Scale-
depression subscale (HADS-D)39, which consists of seven items. Participants could score from 
zero to 21. The KORA study used the self-administered Patient Health Questionnaire (PHQ-9)40 
representing a depression module that scores each of the nine Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for depression from zero to three. 
The GS study assessed life-time history of depression using the Structured Clinical Interview for 
DSM-IV Disorders (SCID)41. The ARIC study assessed depressive symptoms using the 21-item 
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Maastricht Questionnaire (21-MQ). In all cohorts depressive symptoms were analyzed as 
continuous variable except for GS, which studied depression status as binary trait. 
DNA methylation sample and measurement 
In all cohorts, DNA was extracted from whole blood and methylation levels were assessed using 
the Illumina-Infinium Human Methylation 450K BeadChip (Illumina Inc., San Diego, CA, USA) 
using standard manufacturer’s protocols. The 450K array includes more than 450,000 CpGs and 
is enriched for genic regions, covering 99% of all genes. DNA methylation data pre-processing, 
including quality control (QC) and normalization, was conducted per cohort using study-specific 
methods. In all cohorts, DNA methylation levels were quantified as β-values, which range from 
zero to one, and indicate the proportion of DNA strands in a sample methylated at a specific 
CpG. Detailed information about cohort specific DNA extraction, bisulfite conversion, DNA 
methylation profiling, normalization and QC is described in detail in the Supplementary Text. 
Statistical analysis 
Epigenome-wide association analysis 
In all cohorts, the association between depressive symptoms and CpG sites was assessed using 
linear regression analysis in the R software. In the regression analysis, DNA methylation β-value 
at each CpG site was specified as the dependent variable and the depressive 
symptoms/depression as the predictor of interest. Association analysis was adjusted for age42, 
sex43, smoking35 (assessed at the time of blood sampling for methylation), methylation batch 
effects, white blood cell composition (imputed or directly measured), principal components 
estimated using genome-wide genotype data to control for population stratification and 
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familial relationships when required. Cohort specific details of these analyses are provided in 
the Supplementary Text. Further, sensitivity analysis was performed by adjusting the initial 
model for antidepressant medication use at the time of sample collection. 
To pool the results from independent studies we performed sample-size weighted meta-
analysis in METAL44. We chose the ‘sample-size weighted’ method because of the differences in 
the measurement scales of depressive symptoms across studies. A drawback of using sample-
size weighted method is that no pooled effect estimates are generated. To obtain pooled effect 
estimates we additionally performed inverse-variance weighted meta-analysis for the top sites 
in cohorts that used CES-D 20 item scale for the assessment of depressive symptoms. CpG sites 
missing in more than three of the participating cohorts were removed. In total, 484,516 probes 
were tested for association, giving a Bonferroni-corrected genome-wide significance threshold 
of 0.05/484,516 = 1.03×10-7. All CpG sites suggestive of association (p-value ≤ 10-5) were tested 
for association in the independent replication cohorts using the same model as used in the 
discovery EWAS. Finally, a sample size weighted meta-analysis was performed for all cohorts 
included in the discovery and replication phases in METAL. To evaluate the contribution of each 
study to the association results we generated posterior probabilities of the effects in each study 
(M-values) using the METASOFT package45. M-value and Forest plots for z-scores were 
generated using custom-made scripts in R. For annotating CpG sites we used the annotation 
provided by Illumina and the UCSC database (GRCh37/hg19). 
Gene expression analyses 
To evaluate the downstream effects of the three identified CpG sites in blood we used the BIOS 
database to search for eQTM46. To evaluate whether the expression of the genes associated 
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with or harbored the significant methylation site is associated with major depression (also 
smoking and inflammation to check specificity) we used the MetaXcan package47,48. MetaXcan 
associates the expression of the genes with the phenotype by integrating functional data 
generated by large-scale efforts, e.g., Genotype-Tissue Expression (GTEx) with that of the 
GWAS. MetaXcan is trained on transcriptome models in 44 human tissues from GTEx and is able 
to estimate their tissue-specific effect on phenotypes from GWAS. We used the GTEx-V6p-
HapMap-2016-09-08 database and the publicly available GWAS datasets of major depression49, 
and C-reactive protein50 and smoking51, which represent important potential confounders in 
the present study. 
Causal inference analysis 
To help infer causal relationships, we studied the cis-SNPs identified by the BIOS consortium46 
as instrumental variables for the CpG sites as proposed by Smith et al.52. We checked the 
association of these cis-SNPs with depression, smoking and inflammation in the published 
GWAS of these traits. Similarly, we checked whether the single nucleotide polymorphisms 
(SNPs) associated with inflammation (CRP levels)50, smoking51 and depression7 were associated 
with the identified CPG sites using the BIOS consortium database. We chose smoking and 
inflammation as these are highly correlated with both depression and DNA methylation and 
thus could influence the relationship between depression and DNA methylation. 
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Results 
The mean age in the discovery cohorts ranged from 52.4 years (SD=8.1) in GS to 79.1 years 
(SD=0.57) in LBC1921. Forty-eight percent of the total discovery sample were female. The 
replication cohort comprised 74% women and had an average age of 60.3 years (SD=6.4) (Table 
1). 
Epigenome-wide association analysis 
In the meta-analysis of depressive symptoms of European ancestry, we identified one CpG site 
on chromosome 14q32.32 (cg04987734, CDC42BPB, p-value=4.93×10-8, n=7948) that passed 
the Bonferroni threshold for significance (Table 2, eFigure 1). Further, suggestive association 
was observed at 19 additional CpG sites (Table 2). Adjusting for anti-depressive medication use 
did not meaningfully change the results (eTable 1). No inflation in the test statistic was 
observed (Lambda=1.03, eFigure 2). We tested all 20 CpG sites for association in the replication 
sample. The top CpG site from the discovery (cg04987734) showed nominal association (p-
value<0.05, n=3308) with depressive symptoms in the validation data set (Table 2). In addition, 
significant association of a CpG site (cg12325605; p-value=9.17×10-05, n=3308, Table 2) 
annotated to the ARHGEF3 gene with depressive symptoms was observed in the replication 
sample. 
Meta-analysis of discovery and replication cohorts showed a significant association of both 
cg04987734 (p-value=1.57×10-08, n=11256) and cg12325605 (p-value=5.24×10-09, n=11256) with 
depressive symptoms (Table 2; Figures 1 & 2). Also, an additional intergenic CpG site 
(cg14023999; p-value=5.99×10-08, n=11256) at chromosome 15q26.1 locus showed genome-
wide significant association with depressive symptoms (eTable 2, eFigures 3 & 4). The 
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independent contributions of each cohort to the association signals of the three CpG are 
depicted in eFigure 5 and also provided in eTable 3. For all three CpG sites the association 
signals were not driven by a single cohort but appeared to be linearly related to the sample 
size, suggesting stronger association in larger studies (eFigure 5). Pooled effect estimates in 
cohorts that used CES-D scale suggest that a 1-unit increase in CES-D score increases 
methylation by 0.05% at cg04987734, 0.04% at cg12325605, and 0.03% at cg14023999.  
Gene expression analyses 
Cg04987734 was significantly associated with increased expression of CDC42BPB gene (FDR p-
value=7.7×10-04, n=2101) and cg14023999 was significantly associated with decreased 
expression of SEMA4B (FDR p-value=4.7×10-03, n=2101) in blood (eTable 4). No significantly 
associated gene expression probes were identified for cg12325605 in blood. Further, the 
predicted expression of CDC42BPB gene in the brain (basal ganglia) (effect=0.14, p-
value=2.7×10-03) and of ARHGEF3 in fibroblasts (effect=-0.48, p-value=9.8×10-04) was associated 
with major depression (eTable 5). No association was observed with either smoking or 
inflammation. 
Blood & brain correlation 
We checked the correlation between methylation in blood and various brain regions at the 
three identified sites using a web-based tools, BECon18 and a blood brain DNA methylation 
comparison tool (http://epigenetics.essex.ac.uk/bloodbrain/). BECon showed strong correlation 
between blood and brain DNA methylation, e.g. methylation at cg04987734 in the CDC42BPB 
gene was highly correlated (r=0.81) between blood and the Brodmann area 7 that spans the 
medial and lateral walls of the parietal cortex (eFigure 6). Methylation at the other two sites 
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was negatively correlated with methylation in the Brodmann area 10 than spans anterior 
prefrontal cortex (cg12325605, r=-0.39; cg14023999, r=-0.42) suggesting strong but reverse 
methylation patterns in blood and brain (eFigures 7 & 8). However, the blood brain DNA 
methylation comparison tool that compares DNA methylation between blood and prefrontal 
cortex, entorhinal cortex, superior temporal gyrus and cerebellum, showed only modest 
correlations. For instance, methylation in blood at cg04987734 showed the strongest 
correlation with methylation in superior temporal gyrus (r = 
0.18; http://epigenetics.essex.ac.uk/bloodbrain/?probenameg=cg04987734), while methylation 
in blood at cg12325605 (http://epigenetics.essex.ac.uk/bloodbrain/?probenameg=cg12325605) 
and cg14023999 (http://epigenetics.essex.ac.uk/bloodbrain/?probenameg=cg14023999) 
showed strongest correlation with methylation in cerebellum (r = 0.16 & 0.19 respectively). 
Nevertheless, the findings from the two databases suggest some degree of correlation between 
methylation in blood and methylation in brain for the three identified CpG sites. 
Causal inference 
In the BIOS database we identified two cis-SNPs for cg04987734 and 4 cis-SNPs for cg12325605 
(eTable 6) and none for cg14023999. We took the most significant cis-SNP as the proxy for the 
CpG sites if available. For cg04987734 we used rs751837 as a proxy and for cg12325605 we 
used rs3821412 as a proxy (top cis-SNP rs9880418 was not available in the GWAS of depression, 
smoking or inflammation). Rs751837 was suggestively associated with major depression (p-
value=0.07; albeit in opposite direction) (eTable 7). Rs3821412 was not associated with any of 
the three tested phenotypes. None of the SNPs associated with depression, inflammation or 
smoking was associated with any of the three CpG sites.
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Discussion 
In this large-scale EWAS of depressive symptoms, we identified methylation at three CpG sites 
(cg04987734, cg12325605 and cg14023999) associated with depressive symptoms in the 
middle-aged and elderly persons. Cg04987734 is annotated to the CDC42BPB gene, cg12325605 
to the ARHGEF3 gene, and cg14023999 lies in an intergenic region on chromosome 15q26.1 
locus. The predicted expression of CDC42BPB and ARHGEF3 genes associate with major 
depression in brain and fibroblasts respectively. 
CDC42BPB (CDC42 Binding Protein Kinase Beta) encodes a member of the serine/threonine 
protein kinase family, which is an important downstream effector of CDC42 and plays a role in 
the regulation of cytoskeleton reorganization, cell migration and regulation of neurite 
outgrowth53. CDC42BPB is highly expressed in the 
brain https://www.proteinatlas.org/ENSG00000198752-CDC42BPB/tissue. Hyper-methylation 
of cg04987734 has been associated with increased expression of CDC42BPB in blood46. 
Interestingly, methylation levels at this CpG site (cg04987734) in CDC42BPB gene were also 
previously associated with C-reactive protein (CRP) levels in blood34; and smoking35. In our 
study, however, we adjusted for smoking in the regression model; therefore the association 
between depression and DNA methylation of this CpG site may be independent of smoking 
habits. Also our causal inference analyses provide no support for the possibility that smoking or 
inflammation explained the observed association with depressive symptoms nor the predicted 
expression of the gene showed an association with smoking or inflammation. 
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ARHGEF3 encodes for Rho Guanine Nucleotide Exchange Factor 3 protein. The gene is highly 
expressed (https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue) in adrenal 
glands, brain and uterus. Both ARHGEF3 and CDC42BPB are co-expressed with several members 
of the Rho subfamily (RHOA, RHOB and RHOC; eFigures 9 & 10) of the Rho GTPase family that 
also includes CDC4254. The Rho family of GTPases is a family of small signaling G proteins 
involved in p75 neurotrophin receptor (p75NTR)-mediated signaling55 and semaphorin signaling 
pathways56. P75NTR is a transmembrane receptor for neurotrophic factors of the neurotrophin 
family, which includes the brain-derived neurotrophic factor (BDNF)57. P75NTR is widely 
expressed in the developing central and peripheral nervous system during the period of 
synaptogenesis and developmental cell death58. Both p75NTR and semaphorins are implicated 
in axon guidance59,60. In this context, the third associated CpG site cg14023999 that lies in an 
intergenic region on chromosome 15q26.1 is also interesting. Cg14023999 is associated with 
decreased expression of SEMA4B gene in blood. SEMA4B encodes for Semaphorin 4B protein. 
Sema4B is believed to function through a direct interaction with post-synaptic density protein 
PSD-9561 to promote synapse maturation61-63. The knock-down of Sema4B causes a decrease in 
GABAergic synapse number62 suggesting a role in the assembly of excitatory and inhibitory 
postsynaptic specializations63. Previously cg14023999 was found to be significantly correlated 
with Parkinson’s disease64 and significant association of a CpG site in SEMA4B was observed in 
individuals with schizophrenia carrying the 22q11.2 deletion65. These findings point towards a 
functional of SEMA4B in neuro-psychiatric disorders. When comparing our findings with that of 
the previous EWAS of depression, we did not find an overlap. These studies were small (<100 
individuals) and did not report reproducible results20. 
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To summarize, we report the first EWAS of depressive symptoms. We identified and replicated 
association of two methylation sites in the genome with depressive symptoms. A third site was 
identified in the meta-analysis of discovery and replication cohorts, which requires further 
replication. All three findings point towards axon guidance as the common disrupted pathway 
in depression (http://www.genome.jp/kegg/pathway/hsa/hsa04360.html). Our findings provide 
new insights into the molecular mechanisms underlying the complex pathophysiology of 
depression. 
Strengths and limitations of the study 
This is the largest epigenome-wide study of depressive symptoms reported to date. Our major 
strength is the sample size that enabled detection of a replicable epigenome-wide significant 
locus, which suggests that in blood, DNA methylation signatures associated with depression 
may be subtle and will require large samples to be detected. Using peripheral blood tissue for 
DNA methylation profiling is a limitation of this study, as DNA methylation is known to be tissue 
specific66. While peripheral blood is not considered to be the most relevant tissue for the 
pathophysiology of depression, some sites show correlated methylation profiles between-
tissues15,66. The three sites identified in our study show some degree of correlation between 
methylation in blood and various brain regions. Second, while replication in African-American 
samples suggests that some depressive symptoms related differences in DNA methylation may 
be similar across ethnicities67-69, it may also have resulted in false negatives due to different 
genetic background. Third, in these analyses we mostly used quantitative measures of 
depressive symptoms. Quantitative endo-phenotypes provide powerful alternatives for several 
complex outcomes, for example, hypertension70. This is likely to be especially true for a trait 
19 
 
such as depressive symptoms, for which the severity and duration of illness can be highly 
heterogeneous22. Genome-wide studies of depressive traits, using quantitative endo-
phenotypes, have been suggested to improve statistical power22. However, the use of different 
phenotypic measures by different cohorts means that there may be some loss of statistical 
power due to the heterogeneity in the phenotype assessment. Nevertheless, the top three sites 
in our study were robustly associated with depressive symptoms independent of the depressive 
symptom measure used. Fourth, although we adjusted for potential confounders, the 
possibility of residual confounding cannot be excluded. Antidepressant medication indicates 
treated depression but itself may result in epigenetic modifications involved in depression 
pathophysiology71. Antidepressants can thus mediate or confound the relation between DNA 
methylation and depression. However, in sensitivity analysis additionally adjusted for 
antidepressant medication, our results did not change. Fifth, most cohorts included in this 
EWAS are cohorts of elderly persons. The etiology of depression is more heterogeneous in 
elderly people than in younger and often hidden behind somatic symptoms, either because of 
somatization of the disorder or because of accentuation of symptoms of concomitant illness72. 
This may affect the generalizability of the results to younger populations. Finally, we made an 
attempt to disentangle cause and consequence using SNPs associated with the identified CpG 
sites and depression, inflammation and smoking as instrumental variables. The results did not 
support a causative role yet the association of the predicted gene expression of CDC42BPB in 
brain and ARHGEF3 in fibroblasts with major depression does suggest a possible causal role of 
the regulatory effects of these genes47.  
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Table 1. Descriptive statistics of the discovery and replication cohorts. 
Study Ethnicity N Female 
(%) 
Mean Age 
(SD) 
Current 
smokers 
(%)  
Depressive 
symptoms  
Antidepressant 
medication use 
(%) 
Discovery (N = 7948)       
CHS European 323 194 (60.1) 75.6 (5.2) 173 (53.6) CESD1 (10 item) 19 (5.9) 
FHS European 2722 1508 (53.6) 58.5 (11.6) 948 (34.8) CESD2 (20 item) 251 (16.1) 
HBCS European 122 0 (0) 65.2 (2.7) 24 (19.7) CESD2 (20 item) 11 (9.0) 
KORA European 1727 882 (51.1) 61.0 (8.9) 250 (14.5) PHQ-93 82 (4.7) 
LBC 1921 European 432 261 (60.4) 79.1 (0.6) 194 (44.9) HADS4 15 (3.5) 
LBC 1936 European 916 452 (49.3) 69.6 (0.8) 504 (55) HADS4 30 (3.3) 
RS III European 722 391 (54.2) 59.8 (8.1) 167 (23.1) CESD2 (20 item) 38 (5.3)  
RS BIOS European 757 319 (42.1) 67.6 (5.9) 78 (10.3) CESD2 (20 item) 51 (6.7) 
GSa European 227 151 (64.5) 52.4 (8.1) 46 (19.7) SCID5 44 (18.8) 
Total  7948 4158 (48.4) 65.4 (5.8) 2384 (30.6) - 541 (8.1) 
Replication (N = 3308)       
ARIC African 2297 1445 (63) 56.1 (5.7) 584 (25.4) 21-MQ6 74 (3.3) 
WHI-EMPC European 1011 1011 (100) 64.6 (7.1) 509 (50.3) CES-D/DIS7 61 (6.0) 
Total  3308 2456 (74.2) 60.3 (6.4) 1093 (37.9) - 135 (4.7) 
Characteristics are depicted as mean (SD), unless otherwise specified. 
CHC Cardiovascular health cohort, FHS Framingham Heart Study, HBCS Helsinki Birth Cohort Study, KORA Cooperative Health Research in the 
Augsburg Region, LBC Lothian Birth Cohort, RS Rotterdam Study, GS Generation Scotland Study, and a CASE-CONTROL STUDY, ARIC 
Atherosclerosis Risk in Communities Study and WHI-EMPC the Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated 
Cardiovascular disease; “(in brackets we state number of item of the questionnaires)”. 
1 Irwin, M. et al. 1999. 2 Radloff, LS. et al. 1977. 3 Kroenke, K. et al. 2001. 4 Zigmond, AS. et al. 1983. 5 First, MB. et al. 1996. 6 Wattanakit,K. et 
al. 2005. 7 Burnam, MA. et al. 1988.
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Table 2. Top DNA methylation sites associated with depressive symptoms in the discovery EWAS. 
    Discovery  
(N=7948) 
Replication 
(N=3308) 
 
Meta-analysis 
(N=11256) 
CpG site ID Chr Location Gene symbol P-value P-value P-value 
 cg04987734 14 103415873 CDC42BPB 4.93×10-8 4.82×10-02 1.57×10-08 
cg07012687 17 80195180 SLC16A3 3.47×10-7 1.58×10-01 4.45×10-06 
cg08796240 16 70733832 VAC14 7.43×10-7 2.56×10-01 1.80×10-06 
cg06096336 2 231989800 PSMD1; HTR2B 8.06×10-7 3.01×10-01 2.51×10-06 
cg16745930 10 100220809 HPSE2 1.34×10-6 4.01×10-01 6.26×10-06 
cg09849319 5 1494983 LPCATI1 1.81×10-6 4.64×10-01 1.04×10-04 
cg17237086 22 40814966 MKL1 3.44×10-6 2.51×10-01 6.10×10-06 
cg03985718 2 105924245 TGFBRAP1 3.61×10-6 8.54×10-01 6.53×10-05 
cg21098005 20 44538605 PLTP 4.36×10-6 9.60×10-01 1.01×10-04 
cg16466652 19 6271960 MLLT1 4.39×10-6 3.97×10-01 1.57×10-05 
cg07884764 11 64107517 CCDC88B 5.03×10-6 9.99×10-01 1.25×10-04 
cg01541347 7 4729920 FOXK1 5.64×10-6 3.77×10-01 8.46×10-04 
cg02341197 21 34185927 C21or62 5.84×10-6 2.02×10-01 6.80×10-06 
cg01947751 3 196728969 - 6.23×10-6 6.63×10-01 3.68×10-04 
cg13747876 17 80195402 SLC16A3 6.32×10-6 1.04×10-01 2.93×10-06 
cg12764201 1 105101123 CORT; APITD1 7.15×10-6 7.20×10-01 7.29×10-05 
cg08295111 5 133866097 PHF15 7.87×10-6 5.76×10-01 5.64×10-04 
cg18030453 3 45506216 LARS2 9.16×10-6 3.87×10-03 1.20×10-07 
cg12325605 3 56810151 ARHGEF3 9.62×10-6 9.17×10-05 5.24×10-09 
cg23282441 10 73533927 C10orf54; CDH23 9.69×10-6 1.77×10-01 8.63×10-06 
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Figure legends 
Figure 1: Regional association plot for the top CpG site cg04987734. The horizontal axis depicts 
the position in base pair (hg19) for the entire CDC42BPB gene region. The Vertical axis indicates 
the strength of association in terms of negative logarithm of the association p-value. Each circle 
represents CpG site. Red dashed line indicates the genome-wide significance threshold. Below 
the horizontal axis the figure shows the regulatory information and correlation matrix of other 
CpG sites in the region with the top hit. Color intensity marks the strength of the correlation 
and color the direction of the correlation. Figure is made using web-based plotting tool and R-
based package “CoMET” (http://comet.epigen.kcl.ac.uk:3838/coMET1/). 
Figure 2: Regional association plot for the top CpG site cg12325605. The horizontal axis depicts 
the position in base pair (hg19) for the entire ARHGEF3 gene region. The Vertical axis indicates 
the strength of association in terms of negative logarithm of the association p-value. Each circle 
represents CpG site. Red dashed line indicates the genome-wide significance threshold. Below 
the horizontal axis the figure shows the regulatory information and correlation matrix of other 
CpG sites in the region with the top hit. Color intensity marks the strength of the correlation 
and color the direction of the correlation. Figure is made using web-based plotting tool and R-
based package “CoMET” (http://comet.epigen.kcl.ac.uk:3838/coMET1/). 
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Study-specific details 
 
Cardiovascular Health Study Cohort 
 
Description. The CHS is a population-based cohort study of risk factors for coronary heart disease and 
stroke in adults ≥65 years conducted across four field centers.(1) The original predominantly European 
ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare 
eligibility lists. CHS was approved by institutional review committees at each field center and individuals in 
the present analysis had available DNA and gave informed consent including consent to use of genetic 
information for the study of cardiovascular disease.  
 
DNA methylation sample, measurement, normalization and quality control. DNA methylation was 
measured on a randomly selected subset of 323 European descent participants from study year. The 
samples were randomly selected among participants without presence of coronary heart disease, 
congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic 
attack at study baseline or lack of available DNA at study year 5. 
Methylation measurements were performed at the Institute for Translational Genomics and Population 
Sciences at the Harbor-UCLA Medical Center Institute for Translational Genomics and Population 
Sciences using the Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, CA). Quality 
control was performed in in the minfi R package.(2-4) (version 1.12.0, 
http://www.bioconductor.org/packages/release/bioc/html/minfi.html). Samples with low median intensities 
of below 10.5 (log2) across the methylated and unmethylated channels, samples with a proportion of 
probes falling detection of greater than 0.5%, samples with QC probes falling greater than 3 standard 
deviation from the mean, sex check mismatches, or failed concordance with prior genotyping were 
removed. Methylation values were normalized using the SWAN quantile normalization method.(3) Since 
white blood cell proportions were not directly measured in CHS they were estimated from the methylation 
data using the Houseman method.(5) All association analyses were performed in R using linear mixed 
models with DNA methylation beta values as the outcome. Analyses adjusted for age, gender, current 
smoking status and antidepressant medication. Additionally chip, chip row and column were adjusted for 
as random effects. 
CHS was approved by institutional review committees at each field center and individuals in the present 
analysis had available DNA and gave informed consent including consent to use of genetic information 
for the study of cardiovascular disease. The DNA methylation dataset from CHS can be requested at 
https://chs-nhlbi.org/node/6222. 
 
Depressive symptoms assessment. Depressive symptoms were assessed during an in-person 
interview using the Center for Epidemiology Studies-Depression (CES-D) 10 item scale.  
 
Covariates. Smoking and medication were assessed during an in-person interview, at the time of blood 
assessment for methylation. Smoking was assessed with a standard questionnaire, medications were 
assessed by an inventory of all prescription medication containers used in the 2 weeks prior to the 
interview. 
 
Acknowledgments. Infrastructure for the CHARGE Consortium is supported in part by the National 
Heart, Lung, and Blood Institute grant R01HL105756. The CHS research was supported by NHLBI 
contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, 
N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, 
R01HL087652, R01HL092111, R01HL105756, R01HL103612, R01HL111089, R01HL116747 and 
R01HL120393 with additional contribution from the National Institute of Neurological Disorders and 
Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on 
Aging (NIA) as well as Laughlin Family, Alpha Phi Foundation, and Locke Charitable Foundation. A full 
list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of 
genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI 
grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes 
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Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research 
Center.  
The content is solely the responsibility of the authors and does not necessarily represent the official views 
of the National Institutes of Health.  
 
Framingham Heart Study (FHS) 
 
Description. The Framingham Heart Study (FHS) is a population-based, prospective study. In 1948, the 
Original cohort of 5209 individuals were recruited from Framingham, MA.(6) The offspring cohort was 
recruited in 1971, including 5,124 offspring and spouses of offspring of the FHS Original cohort.(7) 
Offspring participants underwent examinations every four years (except eight years between the first and 
the second examinations).(7)  
 
DNA methylation sample, measurement, normalization and quality control. Peripheral whole blood 
samples were collected from these participants at the eighth examination (2005-2008). Buffy coat 
fractions were obtained and genomic DNA was extracted using the Gentra Puregene DNA extraction kit 
(Qiagen, Venlo, Netherlands). Bisulfite conversion of genomic DNA was performed with the EZ DNA 
Methylation Kit (Zymo Research, Irvine, CA). DNA methylation was measured by Infinium 
HumanMethylation450 BeadChip (Illumina, CA) in two separate labs. All participants provided written 
consent for genetic study.  
QC procedures were performed. Bad samples were excluded if the samples were outliers in 
multidimensional scaling (MDS) analysis, high missing rate (>1%), poor matching to SNP genotype. Low 
quality probes were excluded if these probes had high missing rate (>20%), were mapped to multiple 
locations, had SNP (MAF>5% in EUR 1000G) at CpG site or ≤10 bp of Single Base Extension.(8) About 
440,000 probes remain in ~2,600 FHS participants. A total of 1,680 Offspring participants had both DNA 
methylation and CESD phenotype. The sample characteristics are displayed in Table 1 in the manuscript. 
The DNA methylation dataset from FHS is available on request to Chunyu Liu  e-mail: 
chunyu.liu@nih.gov. 
 
Depressive symptoms assessment. Depressive symptoms were evaluated using the Center for 
Epidemiologic Studies Depression Scale (CES-D)(9), a 20-item scale consisting of 4 factors: depressive 
affect, somatic complaints, positive affect, and interpersonal relations (1). This 20-item, self-report scale, 
designed for use in community studies, has been validated in studies similar to the Framingham Heart 
Study .  The CES-D scale was self-administered in the offspring cohort. Scores on the CES-D range from 
0 to 60, with higher scores reflecting greater depressive symptoms.  
 
Covariates. At each examination, participants underwent a medical history, physical examination, and 
fasting blood sample collection. Clinical covariates were assessed at the same examination cycle as the 
blood sample obtained for DNA methylation. Details of the examination assessments have been 
previously described(10) and are available in detail at http://www.framinghamheartstudy.org/fhs-for-
researchers/. Self-reported cigarette smoking status was divided into three categories. Current smokers 
were defined as those who have smoked at least one cigarette a day within 12 months prior to the blood 
draw, former smokers were defined as those who had ever smoked at least one cigarette a day, but had 
stopped at least 12 months prior to the blood draw, and never smokers reported never having smoked. 
Medication use was ascertained by physicians by detailed review of participant medication lists, and 
participants were asked to bring medication bottles to the clinic examination for review. 
 
Analysis. We followed the analysis plan. Two models were performed. In order to reduce the batch 
effects, we analyzed the DNA methylation in each lab: residuals were obtained by regressing a CpG 
against the batch effects (plate, row and col numbers) and lab-specific principle components that were 
related to the outcome. Residuals from two labs were put together and then regressed against the CESD, 
adjusting for covariates and family structure. Plate ID and family structures were treated as random 
effects in linear mixed models. 
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Model 1. Resid (CpG ~ Batch effects + PCs) (lab-specific) 
Pooled residuals from two labs ~ CESD + Gender + Age + smoking + WBC + family structure 
 
Model 2. Resid (CpG ~ Batch effects + PCs) (lab-specific) 
Pooled residuals from two labs ~ CESD + Gender + Age + smoking + WBC + deprx8 + family structure 
 
Acknowledgements. The Framingham Heart Study is funded by National Institutes of Health contract 
N01-HC-25195. The laboratory work for this investigation was funded by the Division of Intramural 
Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. The 
analytical component of this project was funded by the Division of Intramural Research, National Heart, 
Lung, and Blood Institute, and the Center for Information Technology, National Institutes of Health, 
Bethesda, MD. This project is also supported by grant contract R01 AG054076. Dr. Michael Mendelson 
was supported by the NIH NHLBI K99-HL136875. 
 
Helsinki Birth Cohort Study (HBCS) 
 
Description. The HBCS comprises 13345 individuals (6370 women and 6975 men), born as singletons 
between 1934 and 1944 in one of the two main maternity hospitals in Helsinki and who were living in 
Finland in 1971 when a unique personal identification number was allocated to each member of the 
Finnish population. The HBCS, which has been described in detail elsewhere, has been approved by the 
Ethics Committee of the National Public Health Institute. Register data were linked with permission from 
the Finnish Ministry of Social Affairs and Health and the Finnish National Archives. 
In 2001 – 2004 at an average age of 61.5 years (SD = 2.9 and range = 56.7 – 69.8 years), a randomly 
selected subsample of the cohort comprising 2003 individuals (1075 women and 928 men) was invited to 
a clinical examination including collection of a blood sample for genetic, epigenetic and biochemical 
studies and a psychological survey including a measure of depressive symptoms. For 283 participants, 
extraction of DNA was not successful, or DNA showed gender discrepancy or close relatedness. From 
the remaining sample of 1720 individuals, 115 women and 97 men had been evacuated to Sweden or 
Denmark during the World War II according to the Finnish National Archives' register. To study the effects 
of early separation from parents on methylome, we selected 83 evacuated men with data on age at and 
length of evacuation and of father’s occupational status and 83 non-evacuated controls matched for sex, 
birth year and father's occupational status in childhood for the methylation typing. In this study, the 
analyses are based on 62 evacuated men and 60 non-evacuated controls with full data on CESD 
depressive symptoms, covariates, and methylation profiles. For this group the mean age was 63.5 years 
(SD = 2.8). 
 
DNA methylation sample, measurement, normalization and quality control. DNA methylation 
analysis was performed at the Genetics Core of the Wellcome Trust Clinical Research Facility 
(Edinburgh, UK). Bisulphite conversion of 500 ng input DNA was carried out using the EZ DNA 
Methylation Kit (Zymo Research, Freiburg, Germany). Four microlitres of bisulphite-converted DNA was 
processed using the Infinium HD Assay for Methylation. This was performed using the Illumina 
Methylation 450 k beadchip and Infinium chemistry (Illumina, Inc., San Diego, CA, USA). Each sample 
was interrogated on the arrays against 485 000 methylation sites. The arrays were imaged on the Illumina 
HiScan platform and genotypes were called automatically using GenomeStudio Analysis software version 
2011.1. 
Quality control pipeline was set up using the R-package minfi, including intensity read outs, normalization, 
cell type composition estimation, β- and M-value calculation. We excluded samples with low intensity 
(badSampleCutoff < 10.6) or deviant beta distribution based on visual inspection (n = 5). We did not 
detect any gender discrepancy. Data were normalized with functional normalization (FunNorm). Of the 
probes, we excluded those with detection p-value > 0.01 in > 50 % of samples(11), non-autosomal and 
non-specific binding probes as well as probes with SNPs in the interval for which the Illumina probe is 
designed to hybridize and if they were located close (10bp from query site) to a SNP which had a minor 
allele frequency of ≥0.05. Probes located in the X and Y chromosome were also excluded.  This yielded a 
total number of probes of 424,844. Batch effects were identified by inspecting the association of principal 
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components of the methylation levels with possible technical batches using linear regressions and visual 
inspection of PCA plots using the Bioconductor R package shinyMethyl (version 0.99.3). Identified batch 
effects (i.e. array column) were removed using the Empirical Bayes' (EB) method ComBat(12). Batch 
corrected β-values after ComBat were used for all further statistical analyses. DNA methylation data from 
the HBCS is available on request to Jari Lahti e-mail: jari.lahti@helsinki.fi. 
 
Depressive symptoms assessment. Frequency of depressive symptoms were self-reported with the 20-
item Centre for Epidemiologic Studies Depression scale (CESD).  
 
Covariates. Age, sex, current smoking status, evacuation status (evacuated in childhood or not), and 
antidepressant medication (Model 2) were self-reported at the clinical visit. Blood cell proportions were 
estimated with the Houseman method. First three genotype MDS components were derived from 
genome-wide genotype data. 
 
Analysis. A linear regression of the CESD depressive symptoms score and covariates on each individual 
methylation probe in the array was performed in R. 
 
Acknowledgements. We thank all study participants as well as all involved in the Helsinki Birth Cohort 
Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland (1284859 
ja 12848591), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk 
Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, 
Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, and Scottish Senior Clinical 
Fellowship (SCD/09). We also acknowledge the Genetics Core of the Wellcome Trust Clinical Research 
Facility (Edinburgh, UK) who ran the 450k array for the HBCS samples. 
 
Cooperative Health Research in the Augsburg Region (KORA) 
 
Description. The Cooperative Health Research in the Region of Augsburg study is an independent 
population-based cohort from the region of Augsburg, Southern Germany. Whole blood samples were 
obtained from the KORA F4 survey (examination 2006-2008), a seven-year follow-up study of the KORA 
S4 cohort. Participants gave written informed consent and the study was approved by the local ethics 
committee (Bayerische Landesärztekammer).  
 
DNA methylation sample, measurement, normalization and quality control. Whole blood genomic 
DNA was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) 
according to the manufacturer’s procedure, with the alternative incubation conditions recommended when 
using the Illumina Infinium Methylation Assay. Raw methylation data were extracted using the Illumina 
GenomeStudio software (version 2011.1, Methylation module 1.9.0). Preprocessing was performed using 
R (version 3.0.1). Probes with signals from less than three functional beads, and probes with a detection 
p-value > 0.01 were defined as low-confidence probes. Probes that covered SNPs (MAF in Europeans 
>5%) were excluded from the data set. A color bias adjustment was performed using the R package lumi 
(version 2.12.0) through smooth quantile normalization and background correction based on the negative 
control probes present on the Infinium HumanMethylation BeadChip. This was performed separately for 
the two color channels and chips. β-values corresponding to low-confidence probes were set to missing. 
A 95% call rate threshold was applied on samples and CpG sites. Beta-mixture quantile normalization 
(BMIQ) was applied using the R package wateRmelon, version 1.0.3. Because KORA F4 samples were 
processed on 20 96-well plates in 9 batches, plate and batch effects were investigated using principal 
component analysis and eigenR2 analysis. The DNA methylation dataset from the KORA study is 
available upon request from KORA-gen (https://epi.helmholtz-muenchen.de/). Data requests can be 
submitted online and are subject to approval by the KORA Board. 
 
Depressive symptoms assessment. Depressive symptoms were assessed using the German version of 
the self-administered Patient Health Questionnaire (PHQ-9).(13) PHQ-9 represents a depression module 
that scores each of the nine Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
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criteria for depression from zero to three. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, 
moderately severe and severe depression. It is used to monitor the severity of the depressive symptoms. 
PHQ scores higher or equal to 10 have been shown to have a sensitivity of 88% and a specificity of 88% 
for major depression. PHQ-9 is recommended by the American Psychiatric Association (APA) working 
group for DSM-5 as instrument to evaluate the severity of major depressive disorder according to the new 
DSM-5 criteria. 
 
Covariates. The association between DNA methylation level as the outcome and depression as the 
independent variable was performed using linear regression models, adjusting for age, sex, smoking, 
antidepressants, white blood cell count, and technical covariates (analytic plate and chip position on 
plate). 
Information on sociodemographic variables including sex, age, smoking status and use of 
antidepressants was collected by trained medical staff during a standardized interview. The estimated 
white blood cell proportions were obtained using the method by Houseman et al.(5) 
 
Acknowledgements. The KORA study was initiated and financed by the Helmholtz Zentrum München – 
German Research Center for Environmental Health, which is funded by the German Federal Ministry of 
Education and Research (BMBF) and by the State of Bavaria.  Furthermore, KORA research has been 
supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as 
part of LMUinnovativ. The research leading to these results has received funding from the European 
Union Seventh Framework Programme under grant agreement [n°313010] (Large-scale prospective 
cohort studies - BBMRI-LPC; www.bbmri-lpc.org), [n°602736] (Multi-dimensional omics approach to 
stratification of patients with low back pain - PAIN-OMICS; http://www.painomics.eu/) and under grant 
agreements [n°603288] (Systems Biology to Identify Molecular Targets for Vascular Disease Treatment – 
SysVasc; http://www.sysvasc.eu/).  
The authors are grateful for the commitment and involvement of all the study participants and for the work 
and dedication of the MONICA/KORA Augsburg Study staff. We thank Nadine Lindemann and Franziska 
Scharl for technical support in the DNA methylation measurements that were performed at the Helmholtz 
Zentrum München. 
 
Lothian Birth Cohorts of 1921 (LBC1921) and 1936 (LBC1936) 
 
Description. The LBC1921 and LBC1936 represent relatively healthy older individuals, mostly living in 
the Lothian region of Scotland, born in 1921 and 1936, respectively. They have been involved in 
longitudinal assessments of psychological and medical traits from the age of 79 (LBC1921) or 70 
(LBC1936) years.(14, 15) Here, we report the first wave, with the largest sample size: 433 (60.3% female) 
participants with a mean age of 79.1±0.6 years (range = 77-80) in the LBC1921; 920 (49.5% female) 
participants with a mean age of 69.6±0.8 years (range = 67-71) in the LBC1936. 
 
DNA methylation sample, measurement, normalization and quality control. 514 whole blood 
samples in LBC1921 and 1,004 samples in LBC1936 were taken and DNA extracted using standard 
methods at, respectively, MRC Technology, Western General Hospital, Edinburgh and the Wellcome 
Trust Clinical Research Facility (WTCRF), Western General Hospital, Edinburgh. 485,512 methylation 
probes were typed at the WTCRF. The R minfi package was used to background correct raw intensity 
data and to generate methylation beta-values.(2) Probes with a low (<95%) detection rate (at p < 0.01) 
were removed and manual quality control via inspection of the array control probe signals was used to 
locate and exclude low quality samples (e.g. samples with inadequate hybridisation, bisulfite conversion, 
nucleotide extension or staining signal). Samples with a low call rate (samples with <450,000 probes 
detected at p < 0.01) were excluded based on the Illumina-recommended thresholds. Because the LBC 
samples had previously been genotyped (Illumina 610-Quadv1), genotypes derived from the 65 SNP 
control probes on the methylation array using the wateRmelon package(16) were compared to those on 
the genotyping array. Exclusions were made for samples with a low match of genotypes with SNP control 
probes, potentially indicative of sample contamination or mix-up (n = 9). Additionally, 8 subjects whose 
predicted sex, based on XY probes, did not align with reported sex were eliminated. The DNA methylation 
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dataset from the Lothian Birth Cohorts is available on requests to the Study Director, Ian Deary e-mail: 
ian.deary@ed.ac.uk. 
 
Depressive symptoms assessment. Depressive symptoms were assessed with the Hospital Anxiety 
Depression Scale (17), containing seven items each for anxiety and depression. The total score of the 
seven depression items was used.  
Covariates. Self-reported smoking behavior (current, former and never) and medication use was also 
ascertained in the clinical testing session. The Anatomical Therapeutical Chemical-Code was used to 
code anti-depressants for current- and non-users. Age, sex, the first 4 principal components obtained 
from genotyping array data to index population substructure, B cells, monocytes, CD8T cells, CD4T cells, 
NK cells, position on BeadChip, methylation sample plate, BeadChip, hybridization date (and smoking for 
model 2). White blood cell counts were imputed from the methylation array using the Houseman 
method.(5)  
 
Analysis. A linear regression of the HADS depression score and covariates on each individual 
methylation probe in the array was performed in R (v3.2.3). 
 
Acknowledgements. We thank the cohort participants and team members who contributed to these 
studies. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the UK’s Biotechnology 
and Biological Sciences Research Council (BBSRC), The Royal Society, and The Chief Scientist Office of 
the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age 
UK (The Disconnected Mind project). Methylation typing was supported by the Centre for Cognitive 
Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust Institutional 
Strategic Support Fund, The University of Edinburgh, and The University of Queensland. Analysis of 
these data were carried out within the University of Edinburgh Centre for Cognitive Ageing and Cognitive 
Epidemiology (CCACE). CCACE is supported by funding from the BBSRC, the Medical Research Council 
(MRC), and the University of Edinburgh as part of the cross-council Lifelong Health and Wellbeing 
initiative (MR/K026992/1). Funding from the Australian NHMRC (613608) supported quality control 
analysis of the methylation data. 
 
The Rotterdam Study (RS-III & RS-BIOS) 
 
Description. The Rotterdam Study is a prospective population based cohort study in a well-defined 
suburb in the city of Rotterdam, the Netherlands. The design and prospective of the Rotterdam Study has 
been described in details elsewhere.(18) For the current analysis we used data from individuals aged 45 
years and older that participated in the third cohort of the Rotterdam Study. Samples were obtained in two 
stages. First stage included participants of the first visit of the third cohort (RS-III-1). Second stage was 
obtained as a part of the BBMRI-NL (Biobanking and Biomolecular Research Infrastructure Netherlands) 
– BIOS project and included participants of the fifth visit of the first cohort (RS-I-5), third visit of the 
second cohort (RS-II-3) and second visit of the third cohort (RS-III-2). The subsets from the two stages 
were analyzed individually and then meta-analyzed, together with other cohorts.  
 
DNA methylation sample, measurement, normalization and quality control. In both subsets of in total 
1479 individuals a whole blood DNA methylation was quantified utilizing same methods. DNA was 
extracted from whole peripheral blood, stored in EDTA tubes, by standardized salting out methods. The 
genome-wide DNA-methylation levels were determined using the Illumina HumanMethylation 450K array 
(Illumina, Inc., San Diego, CA, USA).(19) In short, samples (500ng of DNA per sample) were first treated 
with bisulfite using the Zymo EZ-96 DNA-methylation kit (Zymo Research, Irvine, CA, USA). Next, in 
accordance with the manufacturers’ protocol the samples were hybridized to the arrays. The methylation 
percentage of a CpG site was reported as a β-value ranging between 0 for no methylation and 1 for full 
methylation. 
Quality control (QC) of the samples was carried out using Illumina Genome Studio software (v2011.1, 
methylation module version 1.9.0; Illumina). During QC samples with incomplete bisulfite treatment, with a 
low detection rate (< 99 %), or gender swaps, were excluded. Also, probes with a detection p-value > 
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0.01 in > 1 % samples, were filtered out. In total of 474,528 probes passed the QC in the first subset and 
419,937 in the BIOS subset (excluding sex chromosome).Filtered β values were than normalized with 
DASEN implemented in the wateRmelon package of the R statistical software.(16) The DNA methylation 
dataset from the RS should be directed towards the management team of the Rotterdam Study email: 
secretariat.epi@erasmusmc.nl. 
 
Depressive symptoms assessment. Depressive symptoms were assessed with the Dutch version of 
the Centre for Epidemiologic Studies Depression scale (CESD).(20) The CESD scale was designed to 
assess presence and severity of self-reported depressive symptoms.(21) Participants were asked 20 
questions that correspond with criterion based-symptoms associated with depression, and they could 
score from 0-60. The screening for depressive symptoms was performed during the home interview by 
trained research assistants.  
 
Covariates. Age, sex, current smoking status and antidepressant medication were measured using 
standard cohort specific protocols at the time DNA samples were collected. During this interview 
participants reported on their smoking behavior (current, former and never) and psychotropic medication 
use. Moreover, to confirm the self-reported use of antidepressants prescription, the Anatomical 
Therapeutical Chemical-Code(22) data was collected from pharmacies linked records. Exposure to an 
antidepressant was defined as current user and non-user of any antidepressant as described in detail 
elsewhere.(22) White blood cells counts (monocytes, granulocytes and lymphocytes) were measured 
immediately at the research center using a standard hematology analyzer (Beckman Coulter, Pasadena, 
CA, USA). 
 
Analysis. An epigenome-wide linear regression was performed per DNA methylation probe with CESD 
depression score adjusting for covariates in R. Model 1 was adjusted for age, sex, smoking status, batch 
effects and cell composition, while Model 2 was additionally adjusted for antidepressant medication use. 
 
Acknowledgements. The generation and management of the Illumina 450K methylation array data 
(EWAS data) for the Rotterdam Study were executed by the Human Genotyping Facility of the Genetic 
Laboratory of the Department of Internal Medicine, Erasmus MC, and the Netherlands. The EWAS data 
was funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, and by the 
Netherlands Organization for Scientific Research (NWO; project number 184021007) and made available 
as a Rainbow Project (RP3; BIOS) of the Biobanking and Biomolecular Research Infrastructure 
Netherlands (BBMRI-NL). We thank Mr. Michael Verbiest, Ms. Mila Jhamai, Ms. Sarah Higgins, Mr. Marijn 
Verkerk, and Lisette Stolk PhD for their help in creating the methylation database. The Rotterdam Study 
is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for 
the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly 
(RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the 
European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study 
participants, the staff from the Rotterdam Study and the participating general practitioners and 
pharmacists. 
 
Generation Scotland Study (GS) 
 
Description. Generation Scotland: Scottish Family Health Study (GS:SFHS) is a population- and family-
based cohort comprising ~24,000 individuals from the Scottish population. The cohort has been described 
in detail previously.(23) Two hundred and twenty-seven individuals (118 cases, 109 controls) were 
included in the current study. These individuals are of European descent and were aged 40 years or over 
at the time of recruitment to GS:SFHS. Antidepressant usage was determined by self-report at the time of 
recruitment. Blood samples for DNA extraction were obtained at the time of recruitment to GS:SFHS. 
 
DNA methylation sample, measurement, normalization and quality control. Whole blood genomic 
DNA (500 ng) was treated with sodium bisulphite using the EZ-96 DNA Methylation Kit (Zymo Research, 
Irvine, California), according to the manufacturer’s instructions. DNA methylation was assessed using the 
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Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, California), according to the 
manufacturers protocol. Samples were assigned to slides such that gender was counter-balanced. 
Methylation array processing was carried out at the Wellcome Trust Clinical Research Facility, The 
University of Edinburgh. 
Raw intensity (.idat) files were read into R using the minfi package(2), which was used to perform initial 
quality control assessments by assessing signal from the array’s internal control probes. All samples were 
deemed to have performed well based on the output of the control probes. 
Probe and sample filtering was performed using the pfilter function in wateRmelon.(16) Probes were 
excluded if they had a detection p-value ≥ 0.05 in more than 5% samples (n = 1000) or had a beadcount 
of less than 3 in more than 5% samples (n = 466). All samples satisfied an inclusion criterion of having no 
more than 5% probes with a detection p-value ≥ 0.01. The final dataset comprised 484145 probes 
measured in 227 individuals. 
The raw data (β-values) were normalised using the dasen function in wateRmelon.(16) The DNA 
methylation data from the Generation Scotland (GS) data is available on request to e-mail: 
access@generationscotland.org. 
GS has Research Tissue Bank status, and the GS Access Committee reviews applications to ensure that 
they comply with legal requirements, ethics and patient consent. 
 
Assessment of depression. Diagnoses of depression were established by trained researchers who 
administered the screening questions of the Structured Clinical Interview for DSM-IV (SCID)(24) to all 
GS:SFHS participants. Those who screened positive were subsequently assessed using the mood 
disorder sub-sections of the SCID. Major depressive disorder (MDD) was diagnosed in those meeting the 
criteria for MDD whose symptoms could not be better explained by bipolar disorder, a general medical 
condition or substance abuse. 
 
Covariates. The following variables were included as covariates: sex, age, current smoking status; 
family; estimated blood cell counts; batch (methylation slide ID); and methylation-based principal 
components. Antidepressant usage was additionally included as a covariate in a sensitivity analysis 
carried out to assess the contribution of antidepressant use to depression-associated methylation 
differences. 
Smoking status was determined by self-report at the time of blood sample collection and was recorded as 
a binary variable (current smokers vs. non-smokers (never smokers and ex-smokers)). Antidepressant 
usage was also determined by self-report at the time of blood sample collection. No data on 
antidepressant usage was available for seven individuals. 
Estimated proportions of six blood cell types (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells, B-
cells and natural killer cells) were obtained using the estimateCellCounts function in minfi.(5, 25) In order 
to avoid collinearity, one cell type, natural killer cells, was excluded from the analyses. 
Methylation-based principal components were identified using prcomp without scaling. PCA was 
performed on the matrix of residualised β-values obtained after residualising for the other covariates 
included in the model used to identify differentially methylated positions (principal components were 
estimated separately for model 1 and model 2). Principal components that individually accounted for at 
least 1% of the variance were included as covariates. For both models, this resulted in the inclusion of the 
first six principal components. 
As our sample comprised related individuals (100 discordant sib pairs and 27 singletons), it was 
necessary to account for relatedness. This was achieved using the duplicateCorrelation function in 
limma(26, 27) to fit family as a random effect. 
 
Analysis. Differences in DNA methylation associated with the diagnosis of depression were detected 
using the following linear mixed effects models (family was treated as a random effect and all other 
covariates as fixed effects), implemented in limma(27): 
 
Model 1 (primary analysis):  
Methylation (β-values) ~ Depression diagnosis + Gender + Age + Current smoking status + Estimated 
blood cell counts (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells and B-cells)  + Batch + PCs 1-6 
+ Family 
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Model 2 (sensitivity analysis to assess the effect of co-varying for antidepressant usage):  
Methylation (β-values) ~ Depression diagnosis + Gender + Age + Current smoking status + Estimated 
blood cell counts (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells and B-cells) + Batch + PCs 1-6 + 
Antidepressants + Family 
 
Acknowledgements. We are grateful to the participants for their participation in this study.  KLE would 
like to acknowledge the support of the Brain & Behavior Research Foundation through a NARSAD 
Independent Investigator Award, which funded the methylation analysis.  DNA extraction, bisulphite 
conversion and the processing of the Infinium HumanMethylation450 BeadChips were performed at the 
Wellcome Trust Clinical Research Facility, Edinburgh, UK.  Generation Scotland received core support 
from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the 
Scottish Funding Council [HR03006].  Genotyping of the GS:SFHS samples was carried out by the 
Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was 
funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award 
“STratifying Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z).  RMW 
received salary support from award no. R01 MH102068-02 from the National Institutes of Health to DJP, 
R. McCombie and others.  KLE, RMW, AMM and DJP are members of The University of Edinburgh 
Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE), part of the cross council Lifelong 
Health and Wellbeing Initiative (G0700704/84698).  Funding of CCACE from the BBSRC, EPSRC, ESRC 
and MRC is gratefully acknowledged. 
 
Atherosclerosis Risk In Communities (ARIC) Study 
 
Description. The ARIC study is a population-based cohort study of atherosclerosis and clinical 
atherosclerotic diseases.(28) At its inception (1987-1989), 15,792 men and women, including 11,478 
white and 4,266 black participants were recruited from four U.S. communities: Suburban Minneapolis, 
Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi. In 
the first 3 communities, the sample reflects the demographic composition of the community. In Jackson, 
only African-American residents were enrolled. Participants included in this project were 2,297 African-
Americans with DNA methylation and depressive symptoms measures, both collected at visit 2. 
DNA methylation sample, measurement, normalization and quality control. DNA methylation 
analysis was conducted with the Infinium HumanMethylation450 BeadChip (HM450) array (Illumina Inc., 
San Diego, CA) on genomic DNA extracted from blood samples collected at ARIC Visit 2. Assay were 
performed on participants who had not restricted use of their DNA and for whom at least 1 μg of DNA and 
genome-wide genotyping data were available. Details of assay and QC procedures have been previously 
published.(29) Briefly, genomic DNA was treated with sodium bisulfite using the EZ-96 DNA methylation 
kit (Zymo Research Corporation, Irvine, CA) following the manufacturer’s protocol. Bisulfite converted 
DNA was amplified, enzymatically fragmented, purified and hybridized to the HM450 array in accordance 
with the manufacturer’s directions. Methylation typing at 485,577 CpG sites was performed using 
GenomeStudio 2011.1 (Illumina Inc., San Diego, CA). Methylation level for each probe was derived as a 
beta value representing the fractional level of methylation at that location. Quality control analysis was 
performed using the wateRmelon R package.(16) Probe data were excluded if they had a low detection 
rate (<95% at p<0.01) and a high missing rate (greater than 1% across all samples). Sample data were 
excluded based on the following criteria: (1) greater than 5% missing values across all probes; (2) 
possible gender mismatch based on principal component analysis; (3) genotype mismatch based on 24 
SNPs present on the HM450 array. Methylation values were normalized using the Beta MIxture Quantile 
dilation (BMIQ) method.(30) All ARIC Study participants have provided written informed consent for 
genomic studies and this work was conducted in compliance with the Helsinki Declaration. The 
Committee for the Protection of Human Subjects at the University of Texas Health Science Center at 
Houston has approved this research. The DNA methylation dataset from the ARIC Study is available on 
request at https://www2.cscc.unc.edu/aric/distribution-agreements. 
 
Depressive symptoms assessment. Depressive symptoms were assessed at visit 2 using the 21-item 
Maastricht Questionnaire.(31) Responses to the questionnaire are coded as yes = 2, don't know = 1, and 
12 
 
no = 0. Two items, questions 9 and 14, are reversed coded (yes = 0, don't know = 1, no = 2). Responses 
are summed to obtain an overall vital exhaustion score, which ranges from 0 to 42, with higher scores 
representing more exhaustion. Cronbach alpha for internal consistency has been reported as 0.89.(31) 
Although designed to measure vital exhaustion, the 21-item Maastricht Questionnaire has been shown to 
correlate with measures of depressive symptoms(32) and was previously used to assess depressive 
symptoms.(33, 34) 
 
Covariates. Age, sex, current smoking status and antidepressant medication were measured using 
standard cohort specific protocols at visit 2. Blood cell proportions were imputed using the Houseman 
method.(5) Genotype principal components were derived from genome-wide genotype data (Affymetrix 
6.0). 
 
Analysis. Analysis was performed according to a pre-specified analysis plan adjusting for biological and 
technical covariates (see attached spreadsheet for details). 
 
Acknowledgments. The Atherosclerosis Risk in Communities (ARIC) study is carried out as a 
collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts 
(HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, 
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). 
The authors thank the staff and participants of the ARIC study for their important contributions. Funding 
support for “Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium” was provided by the 
NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419).  
 
Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated CVD 
(WHI-EMPC) 
 
Description. WHI-EMPC is an ancillary study of epigenetic mechanisms underlying associations between 
ambient particulate matter (PM) air pollution and cardiovascular disease (CVD) in the Women’s Health 
Initiative clinical trials (CT) cohort. It is funded by the National Institute of Environmental Health Sciences 
(R01-ES020836).(35) 
The WHI-EMPC study population is a stratified, random sample of 2,200 WHI CT participants who were 
examined between 1993 and 2001; had available buffy coat, core analytes, electrocardiograms, and 
ambient concentrations of PM; but were not taking anti-arrhythmic medications at the time. 
As such, WHI-EMPC is representative of the larger, multiethnic WHI CT population from which it was 
sampled:  n = 68,132 participants aged 50-79 years who were randomized to hormone therapy, calcium / 
vitamin D supplementation, and / or dietary modification in 40 U.S. clinical centers at the baseline exam 
(1993-1998) and re-examined in the fasting state one, three, six, and nine years later.(36) 
During participant visits, data on age, race/ethnicity, smoking status, depressive symptoms, and 
antidepressant medication use were obtained. Current analyses were in European Americans and 
involved information collected at the first visit with available DNA methylation (DNAm) data.  
 
DNA Methylation. Genome-wide DNAm at CpG sites was measured using the Illumina 450K Infinium 
Methylation BeadChip, quantitatively represented by beta (the percentage of methylated cytosines over 
the sum of methylated and unmethylated cytosines), and quality controlled using the following filters:  
detection p-values > 0.01 in > 10% of samples, detection p-values > 0.01 in > 1% of probes, yielding 
values of beta at 484,220 sites. DNAm data was normalized using BMIQ(30), then stage- and plate-
adjusted using ComBat. (12)  Modeled epigenome-wide associations also adjusted for principal 
components for ancestral admixture, cell subtype proportions (CD8-T, CD4-T, B cell, natural killer, 
monocyte, and granulocyte)(5), and technical covariates including array, row, and column. Researchers 
seeking opportunities to access Women's Health Initiative data are encouraged to solicit collaboration 
with a WHI Principal Investigator who can sponsor research proposals and provide expertise on study 
design, content, and data analysis.  WHI Principal Investigators are listed 
at https://www.whi.org/researchers/SitePages/WHI%20Investigators.aspx.  Standing policies governing 
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research proposals, data access, data use agreements, presentations and publications are available at 
https://www.whi.org/researchers/SitePages/Write%20a%20Paper.aspx. 
 
Depressive symptoms ascertainment. Depressive symptoms were obtained on the day of DNAm 
collection using a short screening instrument developed by Burnman et al.(37) that combines six items 
from the CES-D that highly correlate with the full instrument (r =0.88)(38) with two items from the 
Diagnostic Interview Schedule (DIS). This CES-D/DIS screening instrument ranges from 0 to 1 with a 
higher score indicating a greater likelihood of depression. 
 
Acknowledgments. The Women’s Health Initiative Epigenetic Mechanisms of PM-Mediated CVD (WHI-
EMPC) is funded by the the National Institute of Environmental Health Sciences (R01-ES020836; 
Whitsel, Baccarelli, Hou).  The WHI program is funded by the National Heart, Lung, and Blood Institute, 
National Institutes of Health, U.S. Department of Health and Human Services through contracts 
HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, 
HHSN268201100004C, and HHSN271201100004C. 
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eTable 1. Top DNA methylation sites associated with depressive symptoms in the discovery 
EWAS: M2 is model additionally adjusted for antidepressant medication. 
 
CpG site ID Chr Location Gene symbol P-value 
 M1 
P-value  
M2 
cg04987734 14 103415873 CDC42BPB 4.93×10-8 3.94×10-8 
cg07012687 17 80195180 SLC16A3 3.47×10-7 4.51×10-7 
cg08796240 16 70733832 VAC14 7.43×10-7 4.06×10-6 
cg06096336 2 231989800 PSMD1;HTR2B 8.06×10-7 2.11×10-6 
cg16745930 10 100220809 HPSE2 1.34×10-6 2.19×10-6 
cg09849319 5 1494983 LPCATI1 1.81×10-6 6.14×10-6 
cg17237086 22 40814966 MKL1 3.44×10-6 1.30×10-5 
cg03985718 2 105924245 TGFBRAP1 3.61×10-6 1.28×10-5 
cg21098005 20 44538605 PLTP 4.36×10-6 7.86×10-6 
cg16466652 19 6271960 MLLT1 4.39×10-6 7.08×10-6 
cg07884764 11 64107517 CCDC88B 5.03×10-6 1.50×10-5 
cg01541347 7 4729920 FOXK1 5.64×10-6 6.66×10-6 
cg02341197 21 34185927 C21or62 5.84×10-6 8.57×10-6 
cg01947751 3 196728969 - 6.23×10-6 5.93×10-6 
cg13747876 17 80195402 SLC16A3 6.32×10-6 1.31×10-5 
cg12764201 1 105101123 CORT;APITD1 7.15×10-6 1.33×10-5 
cg08295111 5 133866097 PHF15 7.87×10-6 1.73×10-5 
cg18030453 3 45506216 LARS2 9.16×10-6 2.44×10-5 
cg12325605 3 56810151 ARHGEF3 9.62×10-6 1.82×10-5 
cg23282441 10 73533927 C10orf54;CDH23 9.69×10-6 5.30×10-6 
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eTable 2. Top DNA methylation sites associated with depressive symptoms in the meta-EWAS 
(N = 11,256). 
 
a Direction of association in all cohorts. Order of cohorts in the direction column: CHS, FHS, GS, HBCS, KORA, 
LBC1921, LBC1936, RS_BIOS, RSIII, ARIC and WHI-EMPC; b Genomic position based on human genome 19 (hg19) 
 
  
MarkerName Weight Zscore P.value Directiona HetPVal CHR MAPINFOb UCSC_RefGene 
cg12325605 11256 5.84 5.24×10-09 +++++++++++ 0.90 3 56810151 ARHGEF3 
cg04987734 11256 5.65 1.57×10-08 ++--+-++++- 4.87×10-03 14 103415873 CDC42BPB 
cg14023999 11256 5.42 5.99×10-08 ++++++++-++ 0.15 15 90543224  
cg18030453 11253 5.29 1.20×10-07 +++-+-++++- 0.47 3 45506216 LARS2 
cg10829227 11254 5.10 3.40×10-07 +++++-+++++ 0.57 19 47200595 PRKD2 
cg07175797 11254 5.07 3.92×10-07 +++-+++-+++ 0.39 16 50317656  
cg07012687 11251 5.05 4.46×10-07 +++-++++++- 0.27 17 80195180 SLC16A3 
cg12728588 11256 5.01 5.43×10-07 +++++++++++ 0.58 1 36025489 NCDN 
cg22069247 11253 4.93 8.23×10-07 +++-+-+++++ 0.74 2 232393256 NMUR1 
cg12526091 11256 4.91 9.00×10-07 +++-+-+++++ 0.85 12 58245042  
cg14012686 11253 4.89 1.01×10-06 ++-+++++++- 0.62 2 74785750 C2orf65 
cg00153395 11255 4.89 1.02×10-06 +++-+++++++ 0.84 1 65327523 JAK1 
cg04583842 10491 4.84 1.33×10-06 +++-+++?+++ 0.31 16 88103117 BANP 
cg03429645 11255 4.82 1.43×10-06 +++++++-+++ 0.67 3 100053188 NIT2 
cg04286697 11256 4.78 1.75×10-06 +++-+++++++ 0.29 2 232259623 B3GNT7 
cg08796240 11256 4.78 1.80×10-06 ++++++++++- 0.25 16 70733832 VAC14 
cg19769147 11255 4.74 2.09×10-06 +++++-++++- 0.17 14 105860954 PACS2 
cg17822325 11253 4.72 2.33×10-06 +++++-+++++ 0.93 1 31896462 SERINC2 
cg06096336 11254 4.71 2.51×10-06 ++-++-+++++ 0.43 2 231989800 PSMD1; HTR2B 
cg10401362 11254 4.69 2.71×10-06 -++-+-+++++ 1.20×10-03 7 157185402 DNAJB6 
cg07467649 11256 4.69 2.75×10-06 +++-+-+++++ 0.36 7 72856462 BAZ1B 
cg13747876 11256 4.68 2.93×10-06 +++++-++++- 0.49 17 80195402 SLC16A3 
cg25392060 11256 4.66 3.10×10-06 +++-+++++++ 0.52 8 142297121  
cg22365240 11250 4.66 3.17×10-06 -++++++++++ 0.98 2 105374995  
cg08631783 11253 4.62 3.83×10-06 -++-+-+-+++ 0.13 15 89418456 ACAN 
cg19269039 11255 4.62 3.84×10-06 ++++++++-++ 0.51 1 111743200 DENND2D 
cg03720762 11256 4.57 4.82×10-06 +++++++-+++ 0.09 17 17604184 RAI1 
cg21604136 11255 4.57 4.93×10-06 ++-++++++++ 0.20 1 9910137 CTNNBIP1 
cg11931558 11252 4.55 5.46×10-06 +++++++++++ 0.82 7 11013742 PHF14 
cg24550880 11255 4.53 5.88×10-06 +++-+-+++++ 0.46 17 79420279 BAHCC1 
cg07372520 11255 4.53 6.01×10-06 +++-+-+++++ 0.42 1 180086434  
cg05827190 11255 4.52 6.08×10-06 +++++-++-++ 0.23 4 681440 MFSD7 
cg19743103 11253 4.52 6.08×10-06 +++--++++++ 0.14 1 6304220 HES3 
cg17237086 11256 4.52 6.09×10-06 +++++-++++- 0.35 22 40814966 MKL1 
cg16745930 11254 -4.52 6.26×10-06 ----------- 0.11 10 100220809 HPSE2 
cg27305772 11256 4.51 6.57×10-06 +++++-+++++ 0.83 11 65630355 MUS81 
cg02341197 11256 4.50 6.80×10-06 +++++-+++++ 0.86 21 34185927 C21orf62 
cg23606718 11255 4.46 8.37×10-06 +++-+++++++ 0.81 2 131513927 FAM123C 
cg23282441 11254 4.45 8.63×10-06 ++--++++++- 0.43 10 73533927 C10orf54; CDH23 
cg17743381 11256 4.44 9.10×10-06 +++++-+++++ 0.70 1 39024825  
cg05251389 11254 4.42 9.67×10-06 +++-+++-+++ 0.71 22 43525330 BIK 
cg26610247 11255 4.42 9.70×10-06 ++---++++++ 0.17 8 142297175  
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eTable 3: Cohort Specific association results for the top three methylation 
sites. 
   cg04987734 cg12325605 cg14023999 
Cohort N Instrument Beta SE P-value Beta SE P-value Beta SE P-value 
ARIC 2297 21-MQ 0.0004 0.0001 2.27E-03 0.0003 0.0001 2.10E-03 0.0004 0.0001 6.39E-06 
CHS 323 CESD(10 item) 0.0007 0.0006 2.79E-01 0.0003 0.0005 4.50E-01 0.0019 0.0006 1.40E-03 
FHS 2722 CESD(20 item) 0.0005 0.0001 5.98E-04 0.0003 0.0001 3.11E-03 0.0003 0.0002 4.44E-02 
GSncAD 227 SCID -0.0010 0.0042 8.12E-01 0.0002 0.0029 9.45E-01 0.0037 0.0037 3.15E-01 
HBCS 122 CESD(20 item) -0.0010 0.0007 1.94E-01 0.0002 0.0007 7.67E-01 0.0008 0.0008 3.49E-01 
KORA 1727 PHQ-9 0.0138 0.0061 2.47E-02 0.0063 0.0047 1.80E-01 0.0055 0.0046 2.30E-01 
LBC1921 432 HADS -0.0015 0.0012 2.31E-01 0.0004 0.0013 7.59E-01 0.0008 0.0013 5.44E-01 
LBC1936 916 HADS 0.0025 0.0007 6.06E-04 0.0009 0.0008 2.73E-01 0.0020 0.0010 3.99E-02 
RS-BIOS 757 CESD(20 item) 0.0004 0.0002 1.30E-01 0.0004 0.0002 2.90E-02 0.0003 0.0003 2.35E-01 
RSIII 722 CESD(20 item) 0.0009 0.0003 5.61E-04 0.0006 0.0002 1.21E-02 0.0000 0.0003 9.84E-01 
WHI 1011 CESD-DIS -0.0013 0.0013 3.06E-01 0.0026 0.0011 1.45E-02 0.0006 0.0013 6.30E-01 
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eTable 4: Significantly associated gene expression (cis) probes with the top CpG sites in blood 
PValue SNPName SNPChr SNPPos ProbeName ProbeChr ProbePos CisTrans SNPType AlleleAssessed OverallZScore Total N HGNCName FDR 
1.81E-05 cg14023999 15 90543224 ENSG00000185033 15 90703836 cis C/T C -4.2877145 2101 SEMA4B 0.00465427 
2.45E-06 cg04987734 14 103415825 ENSG00000198752 14 103523799 cis C/T C 4.7123758 2101 CDC42BPB 7.77E-04 
 
eTable 5: Results of tissue-specific gene expression association with major depressive disorder, inflammation and smoking 
Tissue Trait gene_name zscore effect_size pvalue var_g pred_perf_r2 pred_perf_pval pred_perf_qval n_snps_used n_snps_in_cov n_snps_in_model 
TW_Adipose_Visceral_Omentum_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 0.573826 0.087254 0.566085 0.111695 0.089826 3.40E-05 7.19E-05 29 35 35 
TW_Cells_Transformed_fibroblasts_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 -1.40383 -0.86543 0.16037 0.010835 0.018025 0.026825161 0.010336124 10 12 12 
TW_Colon_Sigmoid_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 1.761678 0.446355 0.078124 0.055562 0.066145 0.003931831 0.006492176 25 27 27 
TW_Esophagus_Mucosa_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 -0.65451 -0.16739 0.512785 0.070505 0.074162 1.81E-05 1.53E-05 38 41 41 
TW_Pancreas_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 1.67459 0.437689 0.094015 0.058995 0.038509 0.016459269 0.014848021 24 30 30 
TW_Pituitary_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 -1.72174 -0.48817 0.085116 0.042863 0.068916 0.014032363 0.022131184 7 7 7 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 1.25774 0.368267 0.208486 0.031532 0.028805 0.017399678 0.013340492 14 15 15 
TW_Whole_Blood_0.5.db.CPD.csv:ENSG00000163947.7 Smoking ARHGEF3 1.012799 1.146626 0.311156 0.020622 0.013538 0.032482103 0.015078958 11 11 11 
TW_Adipose_Visceral_Omentum_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 -0.29108 -0.00248 0.770994 0.111695 0.089826 3.40E-05 7.19E-05 29 35 35 
TW_Cells_Transformed_fibroblasts_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 0.320047 0.010991 0.748933 0.010835 0.018025 0.026825161 0.010336124 10 12 12 
TW_Colon_Sigmoid_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 -0.54925 -0.00879 0.582837 0.055562 0.066145 0.003931831 0.006492176 25 27 27 
TW_Esophagus_Mucosa_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 -0.26342 -0.0027 0.792227 0.070505 0.074162 1.81E-05 1.53E-05 38 41 41 
TW_Pancreas_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 -0.22747 -0.00423 0.820055 0.058995 0.038509 0.016459269 0.014848021 24 30 30 
TW_Pituitary_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 0.138821 0.002983 0.889592 0.042863 0.068916 0.014032363 0.022131184 7 7 7 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 -1.19529 -0.03317 0.231973 0.031532 0.028805 0.017399678 0.013340492 14 15 15 
TW_Whole_Blood_0.5.db.CRP.csv:ENSG00000163947.7 Inflammation ARHGEF3 0.333525 0.007544 0.738738 0.020622 0.013538 0.032482103 0.015078958 11 11 11 
TW_Adipose_Visceral_Omentum_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 0.412344 0.026542 0.680087 0.076475 0.089826 3.40E-05 7.19E-05 21 35 35 
TW_Cells_Transformed_fibroblasts_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 3.294991 0.478392 0.000984 0.011767 0.018025 0.026825161 0.010336124 7 12 12 
TW_Colon_Sigmoid_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 -0.03845 -0.0048 0.96933 0.037719 0.066145 0.003931831 0.006492176 17 27 27 
TW_Esophagus_Mucosa_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 1.307325 0.169943 0.191102 0.014953 0.074162 1.81E-05 1.53E-05 17 41 41 
TW_Pancreas_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 -1.31115 -0.15241 0.189806 0.025828 0.038509 0.016459269 0.014848021 18 30 30 
TW_Pituitary_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 0.577174 0.062648 0.563822 0.02709 0.068916 0.014032363 0.022131184 5 7 7 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 -0.88823 -0.11591 0.374415 0.021688 0.028805 0.017399678 0.013340492 8 15 15 
TW_Whole_Blood_0.5.db.PGC.MDD.csv:ENSG00000163947.7 Major depression ARHGEF3 0.688083 0.092211 0.4914 0.013738 0.013538 0.032482103 0.015078958 5 11 11 
TW_Brain_Nucleus_accumbens_basal_ganglia_0.5.db.CPD.csv:ENSG00000198752.5 Smoking CDC42BPB -1.13679 -0.17847 0.255628 0.196678 0.071375 0.009631025 0.016237748 40 49 49 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CPD.csv:ENSG00000198752.5 Smoking CDC42BPB 0.737376 0.346989 0.460894 0.019126 0.023587 0.031624402 0.022043433 9 15 15 
TW_Uterus_0.5.db.CPD.csv:ENSG00000198752.5 Smoking CDC42BPB 0.696997 0.085148 0.485805 0.185883 0.159989 0.000602084 0.003284848 34 42 42 
TW_Brain_Nucleus_accumbens_basal_ganglia_0.5.db.CRP.csv:ENSG00000198752.5 Inflammation CDC42BPB -0.94649 -0.00942 0.343897 0.206345 0.071375 0.009631025 0.016237748 41 49 49 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CRP.csv:ENSG00000198752.5 Inflammation CDC42BPB -0.66407 -0.02531 0.506646 0.019126 0.023587 0.031624402 0.022043433 9 15 15 
TW_Uterus_0.5.db.CRP.csv:ENSG00000198752.5 Inflammation CDC42BPB 1.266537 0.013667 0.205321 0.185883 0.159989 0.000602084 0.003284848 34 42 42 
20 
 
TW_Brain_Nucleus_accumbens_basal_ganglia_0.5.db.PGC.MDD.csv:ENSG00000198752.5 Major depression CDC42BPB -3.00471 -0.14497 0.002658 0.12281 0.071375 0.009631025 0.016237748 33 49 49 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.PGC.MDD.csv:ENSG00000198752.5 Major depression CDC42BPB -0.14192 -0.02278 0.887144 0.015369 0.023587 0.031624402 0.022043433 9 15 15 
TW_Uterus_0.5.db.PGC.MDD.csv:ENSG00000198752.5 Major depression CDC42BPB 2.249692 0.08074 0.024469 0.173171 0.159989 0.000602084 0.003284848 33 42 42 
TW_Adipose_Visceral_Omentum_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.938201 0.329019 0.348141 0.029282 0.058048 0.000954481 0.001370544 8 9 9 
TW_Artery_Aorta_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 2.008999 0.955071 0.044537 0.017738 0.021501 0.039769694 0.022096813 17 23 23 
TW_Artery_Tibial_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 1.897563 1.311104 0.057754 0.007106 0.012703 0.057380821 0.0238277 4 6 6 
TW_Brain_Putamen_basal_ganglia_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B -1.19224 -0.18487 0.233168 0.208912 0.082556 0.00886192 0.017125428 43 48 48 
TW_Cells_EBV-transformed_lymphocytes_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.234431 0.175335 0.81465 0.054498 0.035753 0.04392222 0.041637927 21 26 26 
TW_Esophagus_Mucosa_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 2.2019 0.591895 0.027672 0.063085 0.145442 9.20E-10 1.43E-09 32 39 39 
TW_Heart_Atrial_Appendage_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.30938 -0.01417 0.757032 0.020932 0.025039 0.046356302 0.034806914 26 29 29 
TW_Heart_Left_Ventricle_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 1.05791 0.130107 0.290096 0.075275 0.141574 8.79E-08 2.59E-07 20 23 23 
TW_Lung_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.810632 0.074346 0.417577 0.021566 0.024632 0.008760454 0.005973537 18 21 21 
TW_Muscle_Skeletal_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.421554 0.231807 0.673351 0.0118 0.104255 3.33E-10 5.83E-10 10 13 13 
TW_Pancreas_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 2.008163 -0.99542 0.044626 0.066281 0.056007 0.003662688 0.004143342 18 24 24 
TW_Pituitary_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 1.162093 0.214899 0.245198 0.323144 0.194396 1.92E-05 0.000105887 63 78 78 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 2.256836 0.438941 0.024018 0.081822 0.188317 2.10E-10 8.25E-10 18 23 23 
TW_Skin_Sun_Exposed_Lower_leg_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 1.745065 0.235792 0.080974 0.094417 0.171147 6.47E-14 1.40E-13 48 62 62 
TW_Spleen_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 1.007384 0.282903 0.31375 0.059964 0.048955 0.037183669 0.036604122 26 28 28 
TW_Stomach_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B -0.28295 -0.10299 0.777212 0.044824 0.053373 0.002436732 0.003789078 13 14 14 
TW_Whole_Blood_0.5.db.CPD.csv:ENSG00000185033.10 Smoking SEMA4B 0.842899 0.295704 0.399285 0.088636 0.121142 4.64E-11 7.68E-11 29 33 33 
TW_Adipose_Visceral_Omentum_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.171927 0.004716 0.863495 0.029282 0.058048 0.000954481 0.001370544 8 9 9 
TW_Artery_Aorta_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.201591 0.044835 0.229522 0.018118 0.021501 0.039769694 0.022096813 18 23 23 
TW_Artery_Tibial_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.904067 0.04806 0.36596 0.007106 0.012703 0.057380821 0.0238277 4 6 6 
TW_Brain_Putamen_basal_ganglia_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.426944 0.015032 0.153596 0.208912 0.082556 0.00886192 0.017125428 43 48 48 
TW_Cells_EBV-transformed_lymphocytes_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B -0.76219 -0.01427 0.445946 0.054498 0.035753 0.04392222 0.041637927 21 26 26 
TW_Esophagus_Mucosa_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B -0.07335 0.001549 0.941526 0.065061 0.145442 9.20E-10 1.43E-09 33 39 39 
TW_Heart_Atrial_Appendage_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B -0.56168 -0.01964 0.574336 0.020932 0.025039 0.046356302 0.034806914 26 29 29 
TW_Heart_Left_Ventricle_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.655161 0.011925 0.512364 0.075275 0.141574 8.79E-08 2.59E-07 20 23 23 
TW_Lung_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.489939 0.039174 0.624177 0.024272 0.024632 0.008760454 0.005973537 20 21 21 
TW_Muscle_Skeletal_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.749909 0.071652 0.080134 0.0118 0.104255 3.33E-10 5.83E-10 10 13 13 
TW_Pancreas_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B -0.63832 -0.01156 0.523264 0.066281 0.056007 0.003662688 0.004143342 18 24 24 
TW_Pituitary_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.650747 0.00577 0.51521 0.33837 0.194396 1.92E-05 0.000105887 67 78 78 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.130898 0.020226 0.258098 0.094501 0.188317 2.10E-10 8.25E-10 20 23 23 
TW_Skin_Sun_Exposed_Lower_leg_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.713745 0.040153 0.086576 0.118149 0.171147 6.47E-14 1.40E-13 52 62 62 
TW_Spleen_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.883423 0.015798 0.377008 0.059964 0.048955 0.037183669 0.036604122 26 28 28 
TW_Stomach_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 1.429465 0.026123 0.152871 0.044824 0.053373 0.002436732 0.003789078 13 14 14 
TW_Whole_Blood_0.5.db.CRP.csv:ENSG00000185033.10 Inflammation SEMA4B 0.363388 0.007313 0.716315 0.088917 0.121142 4.64E-11 7.68E-11 30 33 33 
TW_Adipose_Visceral_Omentum_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B 0.068051 0.007986 0.945745 0.011719 0.058048 0.000954481 0.001370544 6 9 9 
TW_Artery_Aorta_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.20747 -0.15445 0.22725 0.023666 0.021501 0.039769694 0.022096813 15 23 23 
TW_Artery_Tibial_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.76085 -0.45061 0.446749 0.000618 0.012703 0.057380821 0.0238277 4 6 6 
TW_Brain_Putamen_basal_ganglia_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.30872 -0.01316 0.757534 0.050781 0.082556 0.00886192 0.017125428 24 48 48 
TW_Cells_EBV-transformed_lymphocytes_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.26112 -0.10196 0.207266 0.035338 0.035753 0.04392222 0.041637927 15 26 26 
TW_Esophagus_Mucosa_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B 0.708132 0.033001 0.478864 0.112392 0.145442 9.20E-10 1.43E-09 23 39 39 
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TW_Heart_Atrial_Appendage_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.538 -0.05781 0.590577 0.019937 0.025039 0.046356302 0.034806914 19 29 29 
TW_Heart_Left_Ventricle_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.85409 -0.07551 0.393054 0.030514 0.141574 8.79E-08 2.59E-07 12 23 23 
TW_Lung_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.25233 -0.03736 0.800788 0.018843 0.024632 0.008760454 0.005973537 10 21 21 
TW_Muscle_Skeletal_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -0.65097 -0.07568 0.515066 0.017356 0.104255 3.33E-10 5.83E-10 7 13 13 
TW_Pancreas_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B 0.038939 0.028788 0.968939 0.024748 0.056007 0.003662688 0.004143342 13 24 24 
TW_Pituitary_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.259 -0.03792 0.208032 0.271517 0.194396 1.92E-05 0.000105887 49 78 78 
TW_Skin_Not_Sun_Exposed_Suprapubic_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B 0.134409 -0.00241 0.893079 0.051952 0.188317 2.10E-10 8.25E-10 14 23 23 
TW_Skin_Sun_Exposed_Lower_leg_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.64358 -0.09774 0.100264 0.070973 0.171147 6.47E-14 1.40E-13 33 62 62 
TW_Spleen_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.8754 -0.13162 0.060738 0.045648 0.048955 0.037183669 0.036604122 16 28 28 
TW_Stomach_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B -1.92961 -0.16994 0.053655 0.033186 0.053373 0.002436732 0.003789078 7 14 14 
TW_Whole_Blood_0.5.db.PGC.MDD.csv:ENSG00000185033.10 Major depression SEMA4B 1.294453 0.095496 0.195509 0.048565 0.121142 4.64E-11 7.68E-11 17 33 33 
 
eTable 6: Significantly associated (cis) SNPs with the top CpG sites 
PValue SNPName SNPChr SNPChrPos ProbeName ProbeChr ProbePos CisTrans SNPType AlleleAssessed OverallZScore Total N eQTMGene FDR 
6.72E-122 rs9880418 3 56809820 cg12325605 3 56810175 cis A/G A -23.4786941 3841  0 
7.41E-09 rs751837 14 103484825 cg04987734 14 103415849 cis T/C C -5.781334 3841 CDC42BPB 6.09E-06 
1.41E-08 rs3821412 3 56787451 cg12325605 3 56810175 cis T/C T 5.6722757 3841  1.47E-05 
1.95E-06 rs13081650 3 56941112 cg12325605 3 56810175 cis T/C C -4.7589465 3841  0.001692 
1.18E-05 rs4398049 14 103438905 cg04987734 14 103415849 cis A/G A -4.381021 3841 CDC42BPB 0.007461 
0.0001065 rs78561280 3 56889061 cg12325605 3 56810175 cis C/T T 3.8752347 3841  0.048648 
 
eTable 7: Results of causal inference analyses 
CpG site  cg04987734  cg12325605 
cis-SNP  rs751837  rs3821412 
TRAITS effect allele Effect Pvalue effect allele Effect Pvalue 
MDD T 0.9415 0.0786 T 1.02 0.2906 
CRP T 0.0055 0.5807 T -0.0048 0.442 
CPD T 0.2179 0.08687 T 0.039 0.6344 
MDD: major depressive disorder 
CRP: C-reactive protein 
CPD: Cigarettes per day 
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eFigure 1: Genome-wide association plot of the discovery EWAS. 
Horizontal axis depicts chromosomes and vertical axis depicts the negative logarithm of the association p-value. Each dot represents 
a CpG site. The solid red line indicates the genome-wide significance threshold and blue solid line indicates the suggestive threshold. 
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eFigure 2: Quantile-quantile plots for the discovery EWAS. Horizontal axis depicts the 
expected negative logarithm of the association p-value, while the vertical axis shows the 
observed negative logarithm of the association p-value (λ = 1.030). 
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eFigure 3: Genome-wide association plot of the meta-analysis of discovery and replication EWAS. 
Horizontal axis depicts chromosomes and vertical axis depicts the negative logarithm of the association p-value. Each dot represents 
a CpG site. The solid red line indicates the genome-wide significance threshold and blue solid line indicates the suggestive threshold. 
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eFigure 4: Quantile-quantile plot of the meta-analysis of discovery and replication EWAS (λ = 
1.088). Horizontal axis depicts the expected negative logarithm of the association p-value, while 
the vertical axis shows the observed negative logarithm of the association p-value. 
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eFigure 5: Forest and M-value plot for the three significant CpG sites. The left panels illustrate 
the association z-scores for the CpG site for each study against the sample size of the study.  
The red dotted vertical bar represents the nominal significance level (z-score < 1.96). The right 
panels depict the posterior probability of effect in each study (M-value) against the negative 
logarithm of the p-value for that study. Red dots suggest that the study has an effect (m-value > 
0.9), green dots suggest that the study’s effect is uncertain (0.1 < m-value < 0.9), while blue 
dots (not observed in our case) would suggest that the study has no effect (m-value < 0.1). 
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eFigure 6. Correlation between blood and brain methylation at cg04987734. 
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eFigure 7: Correlation between blood and brain methylation at cg12325605.  
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eFigure 8: Correlation between blood and brain methylation at cg14023999. 
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eFigure 9: Gene network of CDC42BPB using STRINGS network database 
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eFigure 10: Gene network of ARHGEF3 using STRINGS network database 
 
